progesterone receptor positive

progesterone receptor positive

Oncology A status of breast CA cells that have a receptor to which progesterone can attach; up to 80% of Pts with PR+ breast and endometrial CAs respond–ie, have a better prognosis–to hormonal manipulation
References in periodicals archive ?
Estrogen receptor negative/ progesterone receptor positive breast cancer is not a reproducible subtype.
Arno Therapeutics, a company involved in the discovery and development of small molecule drugs, has enrolled its first patient in a Phase I dose escalation trial evaluating onapristone in post-menopausal women with progesterone receptor positive tumours, including breast, endometrial and other solid tumours, it was reported yesterday.
In addition, there was an elevated risk of estrogen receptor positive and progesterone receptor positive tumors in Caucasian women related to a 500 gram per week increase in total red meat intake.
2) In addition, male and female breast cancers differ in regards to expression of steroid hormone receptors (men are more likely to have estrogen and progesterone receptor positive tumors), (2) molecular markers (CerbB-2 and BCL-2 protooncogenes may have no prognostic significance in men, while in women it is associated with poor and favorable prognosis, respectively), (3) and genetics (as in women, men with BRCA-2 mutations are predisposed to develop breast cancer but BRCA-1 mutation does not seem to be a risk factor for breast cancer in men, although it has been described in affected men).
The subgroup analysis revealed that women with estrogen or progesterone receptor positive cancer showed no benefit from the dietary intervention.
Current EPT use was significantly associated only with estrogen receptor positive (ER+) progesterone receptor positive (PR+) tumors (relative risk 1.
b) Oestrogen and progesterone receptor positive were less aggressive, responds to hormonal therapy and less chance of axillary lymph node metastasis.
Biopharmaceutical company Arno Therapeutics Inc (OTC Markets:ARNI) revealed on Monday the submission of an Investigational Medicinal Product Dossier (IMPD) to request the clinical trial authorisation of a Phase I dose escalation study evaluating its lead compound onapristone in progesterone receptor positive tumors in post-menopausal women.
In 106 cases the tumors were progesterone receptor positive and the Recurrence Scores in these cases ranged from 1 to 39, with a mean Recurrence Score of 14.
Consumption of soy isoflavones, found in soybeans and soy products, has increased in recent years and there are concerns about the effect of soy consumption on women with estrogen and progesterone receptor positive breast cancer as tumour growth is dependent on estrogen.